Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies

Experts will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

The Scientist Creative Services Team
Jul 6, 2020

FREE Webinar

Tuesday, July 28, 2020
2:30 - 4:00 PM, Eastern Standard Time

Register Now

SARS-CoV-2 is characterized by its rapid spread and significant human-to-human transmission. With no approved vaccines or treatments yet available, researchers are exploring various medical interventions, including neutralizing monoclonal antibodies (mAbs), to control the global COVID-19 pandemic. The SARS-CoV-2 spike (S) glycoprotein, which promotes entry into host cells, is the main target of neutralizing antibodies. In this multisponsored webinar by The Scientist, a panel of researchers will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

Topics to be covered

  • Human monoclonal antibodies for SARS-CoV-2
  • SARS-CoV-2 neutralizing antibodies for global access

Register Now

Meet the Speakers:

James E. Crowe, Jr., MD
Director, Vanderbilt Vaccine Center
Professor, Pediatrics and Pathology, Microbiology and Immunology
Ann Scott Carrell Chair

Devin Sok, PhD
Senior Director, Antibody Discovery and Development
IAVI